Clinical trials: Ophthalmic Solutions
Dry Eye Syndrome
Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-1 (NCT03764735)
- Testing
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Where
- 7 sites in United States
- Volunteers
- 452 people
- Sponsor
- Mitotech, SA
Corneal Transplantation
Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery
Compare the corneal penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing penetrating keratoplasty (PK)
- Trial name
- NCT00764582
- Testing
- 1.5% levofloxacin ophthalmic solution, 0.5% moxifloxacin ophthalmic solution
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Vision Loss Night, Vision Disorders
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions.
- Trial name
- LYNX-3 (NCT07140783)
- Testing
- 0.75% Phentolamine Ophthalmic Solution
- Where
- 20 sites in United States
- Volunteers
- 580 people
- Sponsor
- Opus Genetics, Inc
Blepharitis
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
- Trial name
- NCT00656539
- Testing
- AzaSite®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Conjunctivitis
A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT03231969
- Testing
- Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Faes Farma, S.A.
Dry Eye Disease, Dry Eye Sensation
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the…
- Conditions
- Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease
- Trial name
- NCT06375343
- Testing
- PRO-240, Optive®
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Mydriasis, Dilation
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
The objectives of this study are: To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine To evaluate the efficacy of…
- Trial name
- MIRA-3 (NCT05134974)
- Testing
- Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
- Where
- 15 sites in United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Normal Volunteers
Formulation Comparison in Normal Volunteers
This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days.
- Trial name
- NCT01250197
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Aerie Pharmaceuticals
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00657579
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Corneal Epithelial Disorders
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
The purpose of this study is to determine whether SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.
- Trial name
- NCT02929823
- Testing
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Where
- 19 sites in United States
- Volunteers
- 130 people
- Sponsor
- Senju Pharmaceutical Co., Ltd.
Dry Eye Disease
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
- Trial name
- NCT06544694
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Dry Eye
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
- Trial name
- NCT06296966
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanda Pharmaceuticals
Conjunctivitis, Bacterial
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis
To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety
- Trial name
- NCT00357773
- Testing
- Azithromycin (T1225)
- Sponsor
- Laboratoires Thea
Bacterial Conjunctivitis
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A randomized, double blind, phase II multicenter trial with the objective of assess the safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens, versus Moxifloxacin, versus Gatifloxacin in…
- Trial name
- Pazufloxacin (NCT02980523)
- Testing
- PRO-157, Vigamox, Zymar®
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Age-Related Macular Degeneration
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in…
- Trial name
- NCT02511613
- Testing
- Squalamine Lactate Ophthalmic Solution, 0.2%, ranibizumab
- Where
- 4 sites in United States
- Sponsor
- Ohr Pharmaceutical Inc.
Glaucoma and Ocular Hypertension
A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study
This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current…
- Trial name
- NCT03691649
- Testing
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Where
- 47 sites in United States
- Volunteers
- 426 people
- Sponsor
- Santen Inc.
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Cataract, Anterior Chamber Inflammation
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber…
- Conditions
- Cataract, Anterior Chamber Inflammation, Pain, Postoperative
- Trial name
- NCT03180255
- Testing
- Dexamethasone phosphate
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Healthy Adult Males Volunteers
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers
To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.
- Trial name
- NCT05905653
- Testing
- STN1012600 ophthalmic solution 0.002%
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Santen Pharmaceutical Co., Ltd.